^
    9d
    Radiosensitization Effect of PARP Inhibitor Talazoparib Involves Decreasing Mitochondrial Membrane Potential and Induction of Cellular Senescence. (PubMed, Curr Issues Mol Biol)
    ER10 values for talazoparib, olaparib rucaparib, ABT888 and niraparib were 1.5, 1.8, 2.8, 1.4, and 1.4, respectively. When the p21 gene was knocked down, both the decrease in mitochondrial membrane potential and senescence level were attenuated, suggesting that p21 is involved in senescence induction after γ-irradiation combined with talazoparib treatment. Taken together, we showed that PARP inhibitor talazoparib treatment in combination with γ-irradiation causes cellular senescence in lung cancer cells, involving p21 function.
    Journal
    |
    CDKN1A (Cyclin-dependent kinase inhibitor 1A)
    |
    Lynparza (olaparib) • Talzenna (talazoparib) • Zejula (niraparib) • Rubraca (rucaparib) • veliparib (ABT-888)
    13d
    Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer (clinicaltrials.gov)
    P1, N=44, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Nov 2025 --> Nov 2026
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    HER-2 negative • PGR positive
    |
    carboplatin • veliparib (ABT-888)
    14d
    Veliparib and Temozolomide in Treating Patients With Acute Leukemia (clinicaltrials.gov)
    P1, N=66, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed
    Trial completion
    |
    RAD51 (RAD51 Homolog A)
    |
    Chr t(15;17)
    |
    temozolomide • veliparib (ABT-888)
    21d
    ACNS1721: Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations (clinicaltrials.gov)
    P2, N=38, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Oct 2025 --> Oct 2026
    Trial completion date
    |
    BRAF (B-raf proto-oncogene)
    |
    IDH wild-type
    |
    temozolomide • veliparib (ABT-888)
    29d
    Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=81, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Oct 2025 --> Oct 2026
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA (Breast cancer early onset)
    |
    HER-2 negative • BRCA mutation
    |
    doxorubicin hydrochloride • cyclophosphamide • veliparib (ABT-888)
    29d
    ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic Cancer (clinicaltrials.gov)
    P1/2, N=64, Completed, Georgetown University | Unknown status --> Completed
    Trial completion
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
    |
    PALB2 mutation • BRCA mutation
    |
    5-fluorouracil • oxaliplatin • veliparib (ABT-888) • leucovorin calcium
    30d
    PARP Inhibitor Maintenance After First-Line Chemotherapy in Advanced-Stage Epithelial Ovarian Cancer: A Systematic Review and Meta-Analysis. (PubMed, JAMA Netw Open)
    Observed treatment efficacy and toxic effects varied across PARP inhibitor regimens; for example, the risk ratio for any recurrence or death in the overall study group ranged from 0.53 (95% CI, 0.40-0.70) for senaparib to 0.83 (95% CI, 0.68-1.00) for olaparib, while the risk ratio for high-grade adverse events ranged from 1.15 (95% CI, 0.64-2.06) for veliparib to 4.73 (95% CI, 2.77-8.07) for niraparib. In this study, no subgroup showed an association between first-line PARP inhibitor maintenance therapy in advanced-stage EOC and improved OS, and findings suggest that the consistency of associated PFS benefits may vary, particularly in homologous recombination proficient and BRCA wild type tumors. Variability in efficacy and toxic effects across subgroups and PARP inhibitor regimens underscores the importance of individualized treatment decisions.
    Clinical • Retrospective data • Review • Journal
    |
    HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset)
    |
    HRD • BRCA wild-type
    |
    Lynparza (olaparib) • Zejula (niraparib) • veliparib (ABT-888) • Paishuning (senaparib)
    3ms
    Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer (clinicaltrials.gov)
    P1/2, N=88, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Aug 2025 --> Aug 2026
    Trial completion date
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    veliparib (ABT-888) • topotecan
    3ms
    PARP inhibitors potentiate proton therapy end-of-range effects by accelerating replication forks and promoting transcription conflict. (PubMed, Int J Radiat Oncol Biol Phys)
    PARPi renders cells hypersensitive to end of range high LET proton irradiation. The potential enhanced proton radiosensitization should be considered during clinical trial design with efforts to limit high physical dose and high LET overlap within normal tissues. Planning techniques that increase the LET within tumors warrants further investigation in combination with PARPi as a novel strategy to overcome therapeutic resistance.
    Journal • BRCA Biomarker • PARP Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • RAD51 (RAD51 Homolog A)
    |
    BRCA wild-type
    |
    veliparib (ABT-888)
    4ms
    Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=121, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Aug 2025 --> Aug 2026
    Trial completion date
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    veliparib (ABT-888) • dinaciclib (MK-7965)
    4ms
    Effectiveness and Safety of PARP Inhibitors in Ovarian Cancer: An Umbrella Review of Systematic Reviews and Meta-Analyses. (PubMed, Crit Rev Oncol Hematol)
    These findings support the continued use of PARPi as maintenance therapy in biomarker-selected ovarian cancer populations, while promoting the need for individualized risk-benefit assessment and further research into resistance mechanisms and predictive biomarkers.
    Review • Journal • BRCA Biomarker • PARP Biomarker
    |
    BRCA (Breast cancer early onset)
    |
    HRD • BRCA wild-type • BRCA mutation
    |
    Lynparza (olaparib) • Zejula (niraparib) • Rubraca (rucaparib) • veliparib (ABT-888)
    5ms
    Safety and Tolerability of Berzosertib, an Ataxia-Telangiectasia-Related Inhibitor, and Veliparib, an Oral Poly (ADP-ribose) Polymerase Inhibitor, in Combination With Cisplatin in Patients With Refractory Solid Tumors. (PubMed, JCO Precis Oncol)
    This combination shows antitumor activity, including in patients with and without homologous recombination-compromised tumors and those previously treated with platinum. Adding berzosertib further increases the DDR response elicited by combination cisplatin/veliparib treatment in BRCA-wildtype patients, indicating increased replication stress at the RP2D/MTD.
    Journal • BRCA Biomarker • PARP Biomarker
    |
    BRCA (Breast cancer early onset) • RAD51 (RAD51 Homolog A)
    |
    BRCA wild-type
    |
    cisplatin • veliparib (ABT-888) • berzosertib (M6620)